Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IFOSFAMIDE Cause Electrocardiogram qt prolonged? 16 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Electrocardiogram qt prolonged have been filed in association with IFOSFAMIDE (IFEX). This represents 0.1% of all adverse event reports for IFOSFAMIDE.

16
Reports of Electrocardiogram qt prolonged with IFOSFAMIDE
0.1%
of all IFOSFAMIDE reports
1
Deaths
14
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From IFOSFAMIDE?

Of the 16 reports, 1 (6.3%) resulted in death, 14 (87.5%) required hospitalization, and 1 (6.3%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IFOSFAMIDE. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does IFOSFAMIDE Cause?

Off label use (2,281) Febrile neutropenia (2,225) Disease progression (1,912) Neutropenia (1,509) Drug ineffective (1,331) Thrombocytopenia (1,227) Anaemia (1,067) Product use in unapproved indication (890) Pyrexia (752) Sepsis (712)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which IFOSFAMIDE Alternatives Have Lower Electrocardiogram qt prolonged Risk?

IFOSFAMIDE vs IGURATIMOD IFOSFAMIDE vs ILOPERIDONE IFOSFAMIDE vs ILOPROST IFOSFAMIDE vs IMATINIB IFOSFAMIDE vs IMBRUVICA

Related Pages

IFOSFAMIDE Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged IFOSFAMIDE Demographics